Multidisciplinary Pain Management: The 2026 Evidence-Based Framework for Complex Patients

Margaret is 72. Knees, back, hands, and a 48-hour stay for a post-op infection that left her more deconditioned than when she came in. Six medications on the chart. She has seen her primary, her rheumatologist, a physical therapist, and a pain clinic intake nurse in eight weeks, and none of them have spoken to each other. This is the patient multidisciplinary pain management is supposed to help. It is also the patient multidisciplinary pain management keeps failing.

The gap is not referral volume. It is workflow. The last three years of peer-reviewed evidence have quietly rewritten what multidisciplinary pain management means in practice. Not additive care. Not a team roster. An architecture: stepped-care delivery, a single coordinator, and outcomes measured in function rather than a single pain number.

The 2022 CDC Clinical Practice Guideline set the floor. The 2023 Beers Criteria update, the 2025 Lancet Neurology rTMS review, the 2025 perioperative psychology meta-analysis, and the VOICE, PEAK, and TOR trials have built the structure on top of it.

The Research Tension: Why "Multidisciplinary" Keeps Failing

The word has been in use for forty years. The workflow has not.

In a 2023 systematic review of 20 RCTs of chronic pain interventions across primary care, outpatient, and long-term care settings, the single variable that predicted clinically meaningful outcomes was not which disciplines were represented on the team. It was whether the program had a named care manager, usually a nurse, who owned the patient's longitudinal plan and coordinated each component.

The VOICE trial tested this directly. Collaborative telehealth with a nurse care manager, a clinical pharmacist, and a pain physician reduced pain severity and opioid use in patients with chronic musculoskeletal pain. A separate long-term care RCT in residents over 75 (n=345) showed the nurse-led pain team produced significant function and pain improvements against usual care.

The reason the word keeps failing is that most programs skip the coordinator role. They assemble the disciplines: a PT, an OT, a psychologist, a nurse, a prescriber. They assume that co-location or shared charting produces integration. The data says it does not.

The Stepped-Care Pain Model: A Workflow, Not a Menu

Once a coordinator is in place, the stepped-care pain model gives the team a sequence. This is the architecture that separates current practice from how pain care was delivered even five years ago.

Step 1 is where most patients should live: structured assessment, patient education, activity guidance, and first-line topical or OTC agents. Topical diclofenac gel has an NNT of 1.8 for acute musculoskeletal pain and a side-effect rate of 4.3% against a placebo rate of 4.6% across 42 studies and 6,740 patients. Real-world cohort data in roughly 22,000 patients per arm found topical NSAIDs were associated with lower rates of death, cardiovascular disease, and GI bleeding than oral acetaminophen.

Step 2 adds structured exercise, oral non-opioid agents, and basic psychological support (pain education, relaxation, sleep, activity pacing). Step 3 is where formal interdisciplinary referrals start: CBT plus physical therapy, occupational therapy-led programs for hand OA, and formal pharmacology consults. Step 4 is reserved for neuromodulation, intensive multidisciplinary rehab, and invasive procedures.

Why Sequencing Matters More Than Component Selection

The 2025 evidence consistently shows that the same intervention produces different results depending on where in the sequence it is delivered. Perioperative psychology is the clearest example: a 2025 meta-analysis of 27 RCTs across 2,990 surgical patients found that psychologist-delivered active interventions (CBT, relaxation) reduced pain by an effect size of -0.45 and anxiety by -0.33. Education alone did not. Post-op delivery outperformed pre-op delivery. Sequence matters.

The same is true for medication selection in older adults. A 2025 cohort of 57,086 older adults with neuropathic pain compared duloxetine and gabapentin on fall-related visits. At 180 days, duloxetine produced 158.21 fall-related visits per 1,000 person-years versus 84.44 for gabapentin (HR 0.52 favoring gabapentin). The medication with the older reputation for fall risk was the safer option. The one most clinicians reach for first was the riskier one.

What Multidisciplinary Pain Management Looks Like in Practice

For Physical Therapists

Twenty-one Cochrane reviews (381 studies, 37,143 participants) confirm what most PTs already suspected: no single exercise modality is superior, and patient preference drives adherence. Function gains are stronger than pain reductions. The 2022–2025 evidence adds a screening filter: FABQ above 14 or PCS above 20 predicts that your program will plateau without a combined physical-psychological referral. In a chronic low back pain network meta-analysis, CBT plus physical therapy produced an SMD of 1.01 for physical function. No single-modality approach reached that bar.

The practice impact is concrete. You are not required to become a CBT provider. You are required to screen early and flag appropriately.

For Occupational Therapists

A 2024 hand OA RCT (n=374, mean age 63.6) found OT-led multimodal care was non-inferior to rheumatologist-led care (28.6% vs 28.4% response rate) and cost-effective. In carpometacarpal OA (n=180), OT-delivered multimodal care was superior on pain, grip, and disability, with a 94.5% probability of cost-effectiveness. Joint protection, adaptive equipment, and thermoplastic splints worn at least four hours daily during functional activity produce outcomes that rival specialist care.

For OT, the implication is scope confidence: your lens is not an adjunct to pain care, it is the evidence base for one of its most validated pathways.

For Registered Nurses and APRNs

Every major multidisciplinary trial converges on the nurse as the care manager. In long-term care, the nurse leads observational pain assessment with PAINAD (Cronbach's α 0.69–0.74) and PACSLAC, which detected pain in 27.1% of cases where clinical judgment found none. APRNs carry the stepped-care pharmacology protocol: topicals at Step 1, duloxetine and other non-opioid adjuvants at Step 2 with age-specific dosing, and opioid tapering (5–10% per month, patient-centered) when deprescribing is indicated. 

Nursing's outcome language translates directly: readmission rates, length of stay, falls, opioid-related adverse events, care transition quality. Every measure is a pain outcome when pain is undertreated or overtreated.

For PTAs and OTAs

Stepped-care gives the rationale behind the parameters. TENS at 50–100 Hz and above 15 mA for 30–60 minutes across a minimum of ten sessions is not a convention. It is the parameter set that separates effective conventional high-frequency TENS from the sham condition in the 2025 knee OA RCT (n=126), where TENS plus home exercise outperformed sham TENS plus exercise on activity pain and knee strength. When you execute the parameters with fidelity, you are the reason the evidence holds.

For LVNs and LPNs

Observational pain assessment, scheduled medication administration, and early recognition of behavioral change as a pain signal are within scope with supervision. In advanced dementia, NRS completion drops to 75.5% with mild impairment and 57.5% with moderate impairment. PAINAD and PACSLAC fill the gap. The LPN at the bedside is often the first to document the change the team acts on.

Where the Evidence Is Still Developing

Three areas are worth watching closely. First, neuromodulation: the 2025 Lancet Neurology review placed high-frequency motor cortex rTMS as a third-line option for neuropathic pain with roughly 7% pain reduction (below the 15% threshold for clinical importance). Anodal tDCS shows moderate-quality evidence with a better cost profile. Spinal cord stimulation retains Level 1 evidence in post-surgical neuropathic pain, CRPS, chronic limb ischemia, angina, and painful diabetic neuropathy. The space between "emerging" and "first-line" is narrowing but not closed.

Second, digital programs. Pooled data across more than 10,000 patients with chronic knee and low back pain show 68% average pain improvement, 73% completion, and $417.52 mean cost savings. The PEAK trial (n=394, mean age 62) found telerehabilitation non-inferior to in-person care at three months and superior at nine. Chronic low back pain dropout rates were 15.7% digital versus 34.3% in-person. Older adults adhere to digital programs better than many clinicians expect. The question is no longer whether digital belongs in the model but where in the stepped-care sequence it fits best.

Third, perioperative prevention. The 2025 meta-analysis and the Toolkit for Optimal Recovery (TOR) trials suggest the post-operative window outperforms the pre-operative window for psychological intervention, and that combined psychosocial plus rehab beats either component alone. Large, multi-site replication is still needed. In the meantime, screening with the Pain Catastrophizing Scale and the FABQ is the practical move.

Product Spotlight:

Multidisciplinary Pain Management and Assessment: Evidence-Based Update

$37.97

This course, Multidisciplinary Pain Management: An Evidence-Based Update, is designed for healthcare professionals such as nurses and allied health clinicians who manage patients experiencing pain. It offers a comprehensive, up-to-date exploration of pain management grounded in the latest clinical evidence… read more

Add to cart

Three Things You Can Do This Week

1. Name the care manager on every complex pain patient. Whether you are the PT, OT, nurse, or APRN, pick one person on the team who owns longitudinal coordination. Put the name in the chart. The 20-RCT review says this one step accounts for most of the team effect.
2. Screen for psychological risk before the third visit. FABQ above 14 or PCS above 20 is your trigger for a combined-care referral. Without this screen, you will plateau on patients whose recovery depends on integrated psychological support.
3. Audit one medication list for topical-first substitution and 2023 Beers flags. Pick one older adult patient. Check whether oral NSAIDs, TCAs, skeletal muscle relaxants, or tramadol could be replaced with topical diclofenac, scheduled acetaminophen (max 2,000 mg/day after 80), or a stepped trial of duloxetine or gabapentin with dose-appropriate titration.

How the 2026 Framework Changes the Conversation

The question is no longer "what can we add to pain care?" The question is "what are we sequencing, and who owns the sequence?" That is the shift from multimodal care, which is additive, to stepped-care pain management, which is architectural.

The framework shows up at two decision points that get made every week in outpatient, acute care, long-term care, and home health. The first is screening: which patients need an early combined-care referral, and which patients can succeed on a Step 1 or Step 2 plan? The second is coordination: does one person on your team own this patient's longitudinal plan, and does that person have the authority and the outcome measures to hold the plan together?

Outcome measures are where many programs still fall apart. Every discipline tracks something different. The 2022–2025 consensus has landed on a shared core: pain intensity (NRS with one-week recall, 96% consensus), pain interference, physical function, psychological wellbeing, and the Patient Global Impression of Change. Until every discipline on a team reports into those five domains, no one can tell whether the program is working.

The Bottom Line

Multidisciplinary pain management in 2026 is not a menu of services. It is a stepped-care workflow with a named coordinator, validated multidimensional outcomes, and a sequencing logic drawn from the 2022–2025 evidence base. Build the workflow and the outcomes follow. Skip the coordinator role, and you get the policy word without the result.

REFERENCES